Buescher E S, McWilliams-Koeppen P
Center for Pediatric Research, Eastern Virginia Medical School, Children's Hospital of the King's Daughters, Norfolk 23510, USA.
Pediatr Res. 1998 Jul;44(1):37-42. doi: 10.1203/00006450-199807000-00006.
We used column chromatography, affinity binding, and bioassay methods to address whether the soluble tumor necrosis factor (TNF)-alpha receptors present in human colostrum and milk bind to and modify TNF-alpha bioactivity. In gel chromatography experiments, soluble TNF-alpha receptor I (sTNFRI) and sTNFRII in human colostrum sequentially increased their molecular sizes from 49 kD to 71 kD and 60 kD, respectively, after addition of increasing molar excesses of recombinant TNF-alpha. Application of colostrum to a TNF-alpha affinity matrix followed by washing and elution resulted in 2925-fold enrichment of sTNFRI, consistent with sTNFRI binding to the TNF-alpha affinity matrix. In other samples of colostrum and milk, the content of both sTNFRI and sTNFRII decreased significantly after passage over the matrix, but the material eluted from the matrix lost the ability to rebind to the TNF-alpha and was not active in a WEHI-13var bioassay for TNF-alpha. Specimens of human colostrum and milk diluted 1:16 shifted the LD50 for TNF-alpha 4-fold in this bioassay, and milk protection of WEHI-13var cells against TNF-alpha was significantly diminished after passage down the TNF-alpha affinity matrix (p < 0.001). Affinity purification of milk sTNFRI using polyclonal anti-sTNFRI produced fractions containing proteins of 30 kD, which could be visualized by Western blot using polyclonal anti-sTNFRI. Addition of this fraction to the WEHI-13var bioassay reversed the effects of 10 pg/mL TNF-alpha in the assay. These data demonstrate that sTNFRI and II from human colostrum and milk bind to TNF-alpha, that both colostrum and milk interfere with the bioactivity of TNF-alpha, and that affinity-purified sTNFRI from human milk blocks the bioactivity of TNF-alpha. These effects may contribute to the anti-inflammatory character of human colostrum and milk.
我们运用柱色谱法、亲和结合法和生物测定法,以探讨人初乳和乳汁中存在的可溶性肿瘤坏死因子(TNF)-α受体是否能结合并改变TNF-α的生物活性。在凝胶色谱实验中,添加递增摩尔过量的重组TNF-α后,人初乳中的可溶性TNF-α受体I(sTNFRI)和sTNFRII的分子大小分别依次从49 kD增加到71 kD和从60 kD增加。将初乳应用于TNF-α亲和基质,随后进行洗涤和洗脱,结果sTNFRI富集了2925倍,这与sTNFRI与TNF-α亲和基质结合相符。在其他初乳和乳汁样本中,经过基质处理后,sTNFRI和sTNFRII的含量均显著降低,但从基质洗脱的物质失去了重新结合TNF-α的能力,并且在针对TNF-α的WEHI-13var生物测定中无活性。在该生物测定中,稀释1:16的人初乳和乳汁样本使TNF-α的半数致死剂量(LD50)改变了4倍,并且乳汁对WEHI-13var细胞的TNF-α保护作用在经过TNF-α亲和基质处理后显著减弱(p < 0.001)。使用多克隆抗sTNFRI对乳汁中的sTNFRI进行亲和纯化,得到了含有30 kD蛋白质的组分,使用多克隆抗sTNFRI通过蛋白质印迹法可观察到这些组分。将该组分添加到WEHI-13var生物测定中,可逆转测定中10 pg/mL TNF-α的作用。这些数据表明,人初乳和乳汁中的sTNFRI和II能与TNF-α结合,初乳和乳汁都会干扰TNF-α的生物活性,并且从人乳中亲和纯化的sTNFRI可阻断TNF-α的生物活性。这些作用可能有助于人初乳和乳汁的抗炎特性。